Pfizer raises full-year sales forecast for Covid-19 vaccine
The US drugmaker now expects full-year sales of $26 billion from the vaccine, up from its prior forecast of about $15 billion
Pfizer Inc on Tuesday raised its forecast for full-year sales of the Covid-19 vaccine it co-developed with Germany's BioNTech SE, as a vaccination drive across the globe intensifies.
The US drugmaker now expects full-year sales of $26 billion from the vaccine, up from its prior forecast of about $15 billion.